DK3294893T3 - Bioproduktion af lentivirale vektorer - Google Patents

Bioproduktion af lentivirale vektorer Download PDF

Info

Publication number
DK3294893T3
DK3294893T3 DK16724811.1T DK16724811T DK3294893T3 DK 3294893 T3 DK3294893 T3 DK 3294893T3 DK 16724811 T DK16724811 T DK 16724811T DK 3294893 T3 DK3294893 T3 DK 3294893T3
Authority
DK
Denmark
Prior art keywords
bioproduction
lentiviral vectors
lentiviral
vectors
Prior art date
Application number
DK16724811.1T
Other languages
English (en)
Other versions
DK3294893T5 (da
Inventor
Chi-Lin Lee
Jeffrey S Bartlett
Original Assignee
Csl Behring Gene Therapy Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Csl Behring Gene Therapy Inc filed Critical Csl Behring Gene Therapy Inc
Application granted granted Critical
Publication of DK3294893T3 publication Critical patent/DK3294893T3/da
Publication of DK3294893T5 publication Critical patent/DK3294893T5/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/70—Vectors containing special elements for cloning, e.g. topoisomerase, adaptor sites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/005—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB
    • C12N2830/006—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB tet repressible
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/40—Vector systems having a special element relevant for transcription being an insulator

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK16724811.1T 2015-05-13 2016-05-12 Bioproduktion af lentivirale vektorer DK3294893T5 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562161133P 2015-05-13 2015-05-13
US201562161152P 2015-05-13 2015-05-13
PCT/US2016/031959 WO2016183260A1 (en) 2015-05-13 2016-05-12 Bio-production of lentiviral vectors

Publications (2)

Publication Number Publication Date
DK3294893T3 true DK3294893T3 (da) 2024-03-04
DK3294893T5 DK3294893T5 (da) 2024-10-07

Family

ID=56072458

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16724811.1T DK3294893T5 (da) 2015-05-13 2016-05-12 Bioproduktion af lentivirale vektorer

Country Status (13)

Country Link
US (3) US10138495B2 (da)
EP (2) EP3294893B1 (da)
JP (3) JP6975643B2 (da)
KR (1) KR102940209B1 (da)
CN (2) CN122278949A (da)
AU (2) AU2016261864B2 (da)
CA (1) CA2985828C (da)
DK (1) DK3294893T5 (da)
ES (1) ES2973118T3 (da)
HK (1) HK1243730A1 (da)
PL (1) PL3294893T3 (da)
RU (1) RU2729385C2 (da)
WO (1) WO2016183260A1 (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3294893T5 (da) * 2015-05-13 2024-10-07 Csl Behring Gene Therapy Inc Bioproduktion af lentivirale vektorer
CA3070242A1 (en) 2017-07-18 2019-01-24 Calimmune, Inc. Compositions and methods for treating beta-hemoglobinopathies
JP7470119B2 (ja) * 2018-08-24 2024-04-17 シーエスエル ベーリング ジーン セラピー インコーポレイテッド 無血清培地におけるベクター産生
CN113518825A (zh) * 2018-12-23 2021-10-19 美国杰特贝林生物制品有限公司 Wiskott-aldrich综合征的造血干细胞基因疗法
CN110684804B (zh) * 2019-10-15 2023-04-18 上海本导基因技术有限公司 递送外源rnp的慢病毒载体及其制备方法
KR20230017799A (ko) * 2020-05-15 2023-02-06 아이벡스솔, 아이엔씨. 세포 및 유전자 요법을 위한 안정한 바이러스 벡터 생산자 세포를 생산하기 위한 조성물 및 방법
CN114181954A (zh) * 2020-09-15 2022-03-15 江苏浦珠生物医药科技有限公司 优化的慢病毒包装系统
WO2022232191A1 (en) 2021-04-26 2022-11-03 Csl Behring L.L.C. Lentiviral vectors useful for the treatment of disease
CN121399150A (zh) 2023-05-25 2026-01-23 美国杰特贝林生物制品有限公司 经修饰载体
WO2025215591A1 (en) 2024-04-12 2025-10-16 Csl Behring L.L.C. Modified vectors for xla gene therapy
WO2025219924A1 (en) * 2024-04-19 2025-10-23 Csl Behring Llc Cell lines overexpressing vesicular stomatitis virus g

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613569B1 (en) * 1999-05-25 2003-09-02 University Of Medicine And Dentistry Of New Jersey Inducible packaging cell lines for lentivirus vectors
AU2003902842A0 (en) * 2003-06-06 2003-06-26 The University Of Queensland Flavivirus replicon packaging system
US8293503B2 (en) * 2003-10-03 2012-10-23 Promega Corporation Vectors for directional cloning
JP2006050956A (ja) * 2004-08-11 2006-02-23 Japan Science & Technology Agency プルキンエ細胞における遺伝子の発現のための発現ベクター
WO2007018318A1 (ja) * 2005-08-10 2007-02-15 National University Corporation Kanazawa University 小脳星状細胞及び／又は籠細胞特異的な遺伝子発現方法
WO2007105744A1 (ja) * 2006-03-08 2007-09-20 National University Corporation Kanazawa University プルキンエ細胞指向性ウイルスベクター
EP2125500A4 (en) * 2007-01-12 2012-09-12 Univ Western Ontario HIV COMBINED VACCINE AND METHOD OF PRIMO VACCINATION / REMINDER
DK2379722T3 (da) * 2008-12-16 2017-01-02 C-Lecta Gmbh Ekspressionsvektor
US20120201794A1 (en) * 2009-07-15 2012-08-09 Calimmune Inc. Dual vector for inhibition of human immunodeficiency virus
JP2014509841A (ja) * 2011-01-18 2014-04-24 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 癌を治療するための組成物および方法
WO2013076309A1 (en) 2011-11-24 2013-05-30 Genethon Scalable lentiviral vector production system compatible with industrial pharmaceutical applications
GB201202516D0 (en) * 2012-02-13 2012-03-28 Ucl Business Plc Materials and methods relating to packaging cell lines
JP2013208107A (ja) * 2012-03-02 2013-10-10 Takara Bio Inc レトロウイルスベクターの製造方法
US20150329640A1 (en) * 2012-12-20 2015-11-19 Bluebird Bio, Inc. Chimeric antigen receptors and immune cells targeting b cell malignancies
WO2014200557A1 (en) * 2013-06-10 2014-12-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of increasing the amount of fetal hemoglobin in a cell and/or mammal
DK3294893T5 (da) 2015-05-13 2024-10-07 Csl Behring Gene Therapy Inc Bioproduktion af lentivirale vektorer
CA3070242A1 (en) 2017-07-18 2019-01-24 Calimmune, Inc. Compositions and methods for treating beta-hemoglobinopathies

Also Published As

Publication number Publication date
JP7469280B2 (ja) 2024-04-16
PL3294893T3 (pl) 2024-04-29
EP4316500A2 (en) 2024-02-07
US20220315950A1 (en) 2022-10-06
AU2016261864A1 (en) 2017-11-23
KR20180002795A (ko) 2018-01-08
AU2016261864B2 (en) 2022-05-26
JP2024083457A (ja) 2024-06-21
DK3294893T5 (da) 2024-10-07
KR102940209B1 (ko) 2026-03-16
JP7833493B2 (ja) 2026-03-19
AU2022218478A1 (en) 2022-09-08
CA2985828A1 (en) 2016-11-17
CN107660231A (zh) 2018-02-02
CA2985828C (en) 2020-07-14
US11299752B2 (en) 2022-04-12
AU2022218478B2 (en) 2025-02-27
JP6975643B2 (ja) 2021-12-01
RU2729385C2 (ru) 2020-08-06
RU2017143141A (ru) 2019-06-13
JP2018516557A (ja) 2018-06-28
US20190085359A1 (en) 2019-03-21
RU2017143141A3 (da) 2019-11-26
EP3294893B1 (en) 2023-12-27
ES2973118T3 (es) 2024-06-18
US10138495B2 (en) 2018-11-27
WO2016183260A1 (en) 2016-11-17
JP2022043022A (ja) 2022-03-15
EP4316500A3 (en) 2024-04-10
HK1243730A1 (zh) 2018-07-20
US20180112233A1 (en) 2018-04-26
EP3294893A1 (en) 2018-03-21
CN122278949A (zh) 2026-06-26

Similar Documents

Publication Publication Date Title
DK3137169T3 (da) Hæmmere af lysin-specifik demethylase-1
DK3554240T3 (da) Kombinationer af aktive forbindelser
DK3851537T3 (da) Behandling af hyperbilirubinæmi
DK3145949T3 (da) Lentivirale vektorer
DK3180331T3 (da) Polymorfer af selinexor
DK3294893T5 (da) Bioproduktion af lentivirale vektorer
EP3352472A4 (en) RECEIVER
DK3259349T3 (da) Dehydrogenase-katalyseret fremstilling af FDCA
DK3514109T3 (da) Hydropyrolyse af biomasseholdige råmaterialer
EP3406336A4 (en) NANO FOIL OF CORE CASE STRUCTURE TYPE
DK3307267T3 (da) Behandling af multipel sklerose
DK3283210T3 (da) Fremgangsmåde
DK3474822T3 (da) Formuleringer af brincidofovir
DK3280408T3 (da) Fremgangsmåde til fremstilling af dicycloplatin
DK3418273T3 (da) Derivater af flavagliner
DK3368044T3 (da) Behandling af hepatisk steatose-relateret oligo-ovulation
DK3113773T3 (da) Krystallinske former af grapiprant
DK3297619T3 (da) Terapeutiske anvendelser af L-4-chlorkynurenin
EP3354171A4 (en) JUICER
IL246509A0 (en) Coordination of multiple components
DK3201323T3 (da) Modificering af bakteriofag
IL254502B (en) Solid forms of menaquinols
PT3445167T (pt) Criopreservação de fases juvenis de perceves
NO2023044I1 (no) capromorelin
EP3378566A4 (en) CENTRIFUGE